In late April, the FDA notified SCYNEXIS that the clinical hold on ibrexafungerp had been lifted and concluded that the Phase 3 MARIO study could resume. The MARIO study is a Phase 3 trial evaluating ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.03 ...

Gain insights from Mersana Therapeutics' Q2 2025 earnings call. Highlights include Emi-Le advancements in TNBC, $15M milestone, and a $77M cash position.

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

At Axtria Ignite 2025 in Princeton, New Jersey, editor-in-chief Jonah Comstock connected with GSK's SVP of enterprise AI and chief digital and technology officer, commercial, Madhavi Ramakrishna.

Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

Revenue (GAAP) for Q2 2025 was $3.1 million, missing the $6.2 million estimate but up from $2.3 million in the same period of 2024. Cost-cutting efforts led to lower research and administrative ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

A powerful wave of optimism continued to wash over global markets on Wednesday, propelling European equities higher as ...